CoChat
Sign Up
Cited by 94

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Increased BACE1-AS long noncoding RNA and β-amyloid levels in heart failure

Greco, Simona, Zaccagnini, Germana, Fuschi, Paola, Voellenkle, Christine, Carrara, Matteo, Sadeghi, Iman, Bearzi, Claudia, Maimone, Biagina, Castelvecchio, Serenella, Stellos, Konstantinos, Gaetano, Carlo, Menicanti, Lorenzo, Martelli, Fabio·2017·Cardiovascular Research
DOI 10.1093/cvr/cvx013
Open this paper in CoChat — free account

Abstract

Aims Antisense long noncoding RNAs (ncRNAs) are transcripts emerging from the opposite strand of a coding-RNA region and their role in heart failure (HF) is largely unknown. Additionally, HF and Alzheimer's disease (AD) share several non-genetic effectors and risk factors. We investigated the regulation of the β-secretase-1 (BACE1) gene and of its antisense transcript BACE1-AS in ischaemic HF. Methods and results BACE1 and BACE1-AS expression was measured in left ventricle biopsies from 18 patients affected by non-end stage ischaemic HF and 17 matched controls. The levels of both transcripts were increased in HF patients. Likewise, both transcripts increased also in a mouse model of ischaemic HF, and their expression was directly correlated. BACE1-AS was expressed by all cardiac cell types and BACE1-AS up- or down-modulation in cultured cardiomyocytes and endothelial cells induced a concordant regulation of the cognate BACE1 transcript. Interestingly, BACE1 increase also induced the intracellular accumulation of its product β-amyloid. In keeping with these findings, higher BACE1 protein and β-amyloid peptide levels were also observed in HF. Moreover, increased β-amyloid 1-40 was also found in the plasma of HF patients. Transcriptomic changes of BACE1-AS overexpressing and β-amyloid 1-40 treated cells were largely overlapping and indicated changes of relevant biological process such as 'cell cycle and proliferation', 'apoptosis', and 'DNA repair' as well as 'TGFβ-, TNFα-, p38-…

Overview

Integrity signals

Registry

Crossref · 10.1093/cvr/cvx013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Through additional substrates, BACE1 has been implicated in inflammation, cardiovascular function, glucose homeostasis, and insulin signaling.

    “Through these additional substrates, BACE1 has been implicated in inflammation, cardiovascular function, glucose homeostasis, and insulin signaling”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [38]

  • Dysregulation of the BACE1/BACE1-AS axis has been implicated in both cardiac dysfunction and epilepsy.

    “Dysregulation of the BACE1/BACE1‐AS axis also has been implicated in both cardiac dysfunction and epilepsy.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [38]

  • Dysregulation of the BACE1/BACE1-AS/Aβ axis is associated with heart failure, with both BACE1-AS and BACE1 found upregulated.

    “Furthermore, the dysregulation of the BACE1/BACE1‐AS/Aβ axis is associated with heart failure, with both BACE1‐AS and BACE1 found upregulated.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [38]

  • Aβ levels are elevated in patients with cardiometabolic diseases including obesity, T2D, and heart failure.

    “However, Aβ levels are elevated in patients with cardiometabolic diseases including obesity, T2D, and heart failure.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [38]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 48

  1. Ziaeian, 2016, Epidemiology and aetiology of heart failure, Nat Rev Cardiol, 13, 368, 10.1038/nrcardio.2016.25 · DOI
  2. Creemers, 2011, Heart failure: advances through genomics, Nat Rev Genet, 12, 357, 10.1038/nrg2983 · DOI
  3. ENCODE Project Consortium, 2012, An integrated encyclopedia of DNA elements in the human genome, Nature, 489, 57, 10.1038/nature11247 · DOI · Paper page
  4. Greco, 2015, Noncoding RNA in age-related cardiovascular diseases, J Mol Cell Cardiol, 83, 142, 10.1016/j.yjmcc.2015.01.011 · DOI
  5. Taft, 2010, Non-coding RNAs: regulators of disease, J Pathol, 220, 126, 10.1002/path.2638 · DOI
  6. Dimmeler, 2015, Long noncoding RNAs and MicroRNAs in cardiovascular pathophysiology, Circ Res, 116, 751, 10.1161/CIRCRESAHA.116.303549 · DOI
  7. Papait, 2013, Long noncoding RNA: a new player of heart failure?, J Cardiovasc Transl Res, 6, 876, 10.1007/s12265-013-9488-6 · DOI
  8. Beltrami, 2014, Noncoding RNAs in diabetes vascular complications, J Mol Cell Cardiol, 89, 1
  9. Devaux, 2015, Long noncoding RNAs in cardiac development and ageing, Nat Rev Cardiol, 12, 415, 10.1038/nrcardio.2015.55 · DOI
  10. Greco, 2016, Long noncoding RNA dysregulation in ischemic heart failure, J Transl Med, 14, 183, 10.1186/s12967-016-0926-5 · DOI
  11. Faghihi, 2008, Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of β-secretase expression, Nat Med, 14, 723, 10.1038/nm1784 · DOI · Paper page
  12. Faghihi, 2010, Evidence for natural antisense transcript-mediated inhibition of microRNA function, Genome Biol, 11, R56, 10.1186/gb-2010-11-5-r56 · DOI · Paper page
  13. Cole, 2009, Linking vascular disorders and Alzheimer’s disease: potential involvement of BACE1, Neurobiol Aging, 30, 1535, 10.1016/j.neurobiolaging.2007.12.012 · DOI
  14. Cole, 2007, The basic biology of BACE1: a key therapeutic target for Alzheimer’s disease, Curr Genom, 8, 509, 10.2174/138920207783769512 · DOI
  15. Hartmann, 1997, Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides, Nat Med, 3, 1016, 10.1038/nm0997-1016 · DOI
  16. Cermakova, 2015, Heart failure and Alzheimer’s disease, J Intern Med, 277, 406, 10.1111/joim.12287 · DOI
  17. Stamatelopoulos, 2015, Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease, J Am Coll Cardiol, 65, 904, 10.1016/j.jacc.2014.12.035 · DOI
  18. Greco, 2012, MicroRNA dysregulation in diabetic ischemic heart failure patients, Diabetes, 61, 1633, 10.2337/db11-0952 · DOI
  19. Limana, 2005, Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation, Circ Res, 97, e73, 10.1161/01.RES.0000186276.06104.04 · DOI
  20. Yan, 2014, Targeting the β secretase BACE1 for Alzheimer’s disease therapy, Lancet Neurol, 13, 319, 10.1016/S1474-4422(13)70276-X · DOI
  21. Porta, 2002, Pigments in aging: an overview, Ann N Y Acad Sci, 959, 57, 10.1111/j.1749-6632.2002.tb02083.x · DOI
  22. Pattison, 2008, Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure, Circulation, 117, 2743, 10.1161/CIRCULATIONAHA.107.750232 · DOI
  23. Agnetti, 2014, Desmin modifications associate with amyloid-like oligomers deposition in heart failure, Cardiovasc Res, 102, 24, 10.1093/cvr/cvu003 · DOI
  24. McLendon, 2015, Proteotoxicity and cardiac dysfunction, Circ Res, 116, 1863, 10.1161/CIRCRESAHA.116.305372 · DOI
  25. Gregory, 1991, Curr Commun Cell Mol Biol 3
  26. Liu, 2014, Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1–AS expression, Mol Med Rep, 10, 1275, 10.3892/mmr.2014.2351 · DOI
  27. Nural-guvener, 2012, BACE1 levels are elevated in congestive heart failure, Neurosci Lett, 532, 7, 10.1016/j.neulet.2012.10.051 · DOI
  28. Nogalska, 2010, Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers–possibly caused by endoplasmic reticulum stress, Neurosci Lett, 474, 140, 10.1016/j.neulet.2010.03.023 · DOI
  29. Vattemi, 2003, BACE1 and BACE2 in pathologic and normal human muscle, Exp Neurol, 179, 150, 10.1016/S0014-4886(02)00025-0 · DOI
  30. Askanas, 2006, Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition, Neurology, 66, S39, 10.1212/01.wnl.0000192128.13875.1e · DOI
  31. Kokjohn, 2011, Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets, Biochim Biophys Acta, 1812, 1508, 10.1016/j.bbadis.2011.07.004 · DOI
  32. Roher, 2009, Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease, Alzheimers Dement, 5, 18, 10.1016/j.jalz.2008.10.004 · DOI
  33. Philippen, 2015, Non-coding RNA in control of gene regulatory programs in cardiac development and disease, J Mol Cell Cardiol, 89, 51, 10.1016/j.yjmcc.2015.03.014 · DOI
  34. McLean, 1999, Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease, Ann Neurol, 46, 860, 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M · DOI
  35. Gianni, 2010, Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy, Circulation, 121, 1216, 10.1161/CIRCULATIONAHA.109.879510 · DOI
  36. Monte, 2014, Protein post-translational modifications and misfolding: new concepts in heart failure, PROTEOMICS–Clin Appl, 8, 534, 10.1002/prca.201400037 · DOI
  37. Sanbe, 2004, Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis, Proc Natl Acad Sci U S A, 101, 10132, 10.1073/pnas.0401900101 · DOI
  38. Zhang, 2014, The toxicity mechanisms of action of Aβ25–35 in isolated rat cardiac myocytes, Molecules, 19, 12242, 10.3390/molecules190812242 · DOI
  39. Hayashi, 2009, Alzheimer disease-associated peptide, amyloid β40, inhibits vascular regeneration with induction of endothelial autophagy, Arterioscler Thromb Vasc Biol, 29, 1909, 10.1161/ATVBAHA.109.188516 · DOI
  40. Eisenhauer, 2000, Toxicity of various amyloid B peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of Dutch-type mutant, J Neurosci Res, 60, 804, 10.1002/1097-4547(20000615)60:6<804::AID-JNR13>3.0.CO;2-1 · DOI
  41. Soriano, 2003, Effect of β-amyloid on endothelial cells: lack of direct toxicity, enhancement of MTT-induced cell death and intracellular accumulation, Neurochem Int, 43, 251, 10.1016/S0197-0186(03)00008-1 · DOI
  42. Dawkins, 2014, Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer’s disease, J Neurochem, 129, 756, 10.1111/jnc.12675 · DOI
  43. Cole, 2007, The Alzheimer’s disease beta-secretase enzyme, BACE1, Mol Neurodegener, 2, 22, 10.1186/1750-1326-2-22 · DOI · Paper page
  44. Mizusawa, 2014, Genetic and clinical advances in congenital long QT syndrome, Circ J, 78, 2827, 10.1253/circj.CJ-14-0905 · DOI
  45. Cai, 2012, b -Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment, EMBO Mol Med, 4, 980, 10.1002/emmm.201101084 · DOI · Paper page
  46. Hu, 2013, BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway, Cell Rep, 4, 40, 10.1016/j.celrep.2013.06.005 · DOI · Paper page
  47. Zhou, 2012, The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo, J Biol Chem, 287, 25927, 10.1074/jbc.M112.377465 · DOI · Paper page
  48. Wang, 2015, The interplay between autophagy and the ubiquitin-proteasome system in cardiac proteotoxicity, Biochim Biophys Acta, 1852, 188, 10.1016/j.bbadis.2014.07.028 · DOI

Cited by

Sorted by citations

Metadata

Authors
Greco, S., Zaccagnini, G., Fuschi, P., Voellenkle, C., Carrara, M., Sadeghi, I., Bearzi, C., Maimone, B., Castelvecchio, S., Stellos, K., Gaetano, C., Menicanti, L., & Martelli, F.
Affiliations
  • Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, Via Morandi, 30 20097 San Donato, Milanese, Milan, Italy;
  • Institute of Cell Biology and Neurobiology (IBCN), National Research Council of Italy (CNR), Monterotondo Scalo, Rome, Italy;
  • Department of Cardiac Surgery, IRCCS Policlinico San Donato, Milan, Italy
  • Laboratory of RNA Metabolism and Vascular Inflammation, Institute of Cardiovascular Regeneration, Centre of Molecular Medicine, Goethe University Frankfurt, Frankfurt/Main, Germany
  • Division of Cardiovascular Epigenetics, Department of Cardiology and Internal Medicine Clinic III, Department of Cardiology, Goethe University, Frankfurt/Main, Germany
Venue
Cardiovascular Research
Publisher
Oxford University Press (OUP)
Published
2017-02-23
Volume
113
Issue
5
Pages
453-463
ISSN
  • 0008-6363
  • 1755-3245
DOI
10.1093/cvr/cvx013
Cited by
94
References
3
Language
en
Funders
  • Ministero della Salute, Fondazione Cariplo (#2013-0887)
  • Telethon-Italy (#GGP14092)
  • AFM Telethon (#1847)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review